| NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | RECRUITING | PHASE3 | 2025-06-02 | 2027-03 | 2026-12 |
| NCT07007806 | Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir | COMPLETED | PHASE1 | 2025-05-09 | 2025-06-28 | 2025-06-28 |
| NCT06911320 | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function | RECRUITING | PHASE1 | 2025-04-09 | 2025-11 | 2025-11 |
| NCT06921941 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin | COMPLETED | PHASE1 | 2025-04-08 | 2025-07-02 | 2025-07-02 |
| NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | RECRUITING | PHASE3 | 2025-04-07 | 2026-12 | 2026-09 |
| NCT06356194 | Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir | COMPLETED | PHASE1 | 2024-04-15 | 2024-05-30 | 2024-05-30 |
| NCT06204679 | Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir | COMPLETED | PHASE1 | 2023-12-14 | 2024-08-25 | 2024-08-25 |
| NCT05904470 | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic HCV | COMPLETED | PHASE2 | 2023-05-30 | 2025-01-28 | 2024-12-09 |
| NCT05905497 | The Study of Bemnifosbuvir in Healthy Japanese Subjects | COMPLETED | PHASE1 | 2023-04-26 | 2023-05-19 | 2023-05-19 |
| NCT05905484 | Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | COMPLETED | PHASE1 | 2023-04-25 | 2023-05-31 | 2023-05-31 |
| NCT05724693 | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2023-01-30 | 2024-04-23 | 2024-04-23 |
| NCT05731843 | Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir | COMPLETED | PHASE1 | 2023-01-30 | 2023-03-15 | 2023-03-15 |
| NCT05629962 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 | COMPLETED | PHASE3 | 2022-11-25 | 2024-05-30 | 2024-04-25 |
| NCT05618314 | Study of AT-527 in Subjects With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2022-10-17 | 2024-06-15 | 2024-06-15 |
| NCT05466240 | Study of AT-752 in Patients With Dengue Infection | TERMINATED | PHASE2 | 2022-04-29 | 2023-01-19 | 2023-01-19 |
| NCT05366439 | Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model | TERMINATED | PHASE1 | 2022-04-22 | 2023-03-16 | 2023-03-16 |
| NCT05256732 | Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal | COMPLETED | PHASE1 | 2022-02-22 | 2022-08-23 | 2022-08-23 |
| NCT05154123 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) | COMPLETED | PHASE1 | 2021-11-16 | 2021-12-23 | 2021-12-23 |
| NCT05137626 | Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) | COMPLETED | PHASE1 | 2021-11-03 | 2021-12-12 | 2021-12-12 |
| NCT04309734 | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects | WITHDRAWN | PHASE1, PHASE2 | 2021-10 | 2022-09 | 2022-06 |
| NCT05004415 | Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) | COMPLETED | PHASE1 | 2021-07-28 | 2021-08-12 | 2021-08-12 |
| NCT04877769 | Bronchopulmonary PK of AT-527 (R07496998) | COMPLETED | PHASE1 | 2021-04-25 | 2021-08-31 | 2021-08-31 |
| NCT04865445 | Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) | COMPLETED | PHASE1 | 2021-04-22 | 2021-05-15 | 2021-05-15 |
| NCT04849299 | Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) | COMPLETED | PHASE1 | 2021-04-18 | 2021-05-10 | 2021-05-10 |
| NCT04722627 | Study of AT-752 in Healthy Subjects | COMPLETED | PHASE1 | 2021-03-09 | 2021-11-14 | 2021-11-14 |
| NCT04784000 | Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 | COMPLETED | PHASE1 | 2021-03-01 | 2021-04-10 | 2021-04-10 |
| NCT04711187 | Study of AT-527 in Healthy Subjects (R07496998) | COMPLETED | PHASE1 | 2020-11-02 | 2021-09-15 | 2021-09-15 |
| NCT04396106 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting | TERMINATED | PHASE2 | 2020-05-26 | 2022-02-28 | 2022-01-10 |
| NCT04019717 | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2019-06-20 | 2020-03-23 | 2020-01-29 |
| NCT03219957 | Study of AT-527 in Healthy and HCV-Infected Subjects | COMPLETED | PHASE1 | 2017-07-06 | 2018-06-20 | 2018-06-20 |